PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 1, 2012, Pages 97-105

  Yang, Jichun ^a   Zhou, Yunfeng ^a   Guan, Youfei ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

diabetic nephropathy; hypertension; kidney injury; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOCOPHEROL; CISPLATIN; DAUNORUBICIN; DOCOSAHEXAENOIC ACID; GAMMA TOCOPHEROL; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; STREPTOZOCIN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; GENE EXPRESSION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY DISEASES; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 83055196577     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834de526     Document Type: Review

References (128)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14.
2. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362:1090-1101.
3. Zheng F, Guan Y. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney Int 2007; 72:1301-1303. (Pubitemid 350126785)
4. Yang X, Downes M, Yu RT, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006; 126:801-810. (Pubitemid 44233631)
5. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123:993-999.
6. Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 2007; 80:1-10. (Pubitemid 47013361)
7. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15:2801-2815. (Pubitemid 41103389)
8. Yang J, Chen L, Zhang X, et al. PPARs and female reproduction: evidence from genetically manipulated mice. PPAR Res 2008; 2008:723243.
9. Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 2008; 294:1032-1047.
10. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007; 72:1367-1373. (Pubitemid 350126770)
11. Zhou Y, Kong X, Zhao P, et al. Peroxisome proliferator-activated receptoralpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 2011; 79:1302-1311.
12. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135:798-800. (Pubitemid 24241266)
13. Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001; 281:1036-1046.
14. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101:1311-1318. (Pubitemid 30158620)
15. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferatoractivated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273:1013-1022.
16. Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferatoractivated receptors and retinoid X receptors in the kidney. Am J Physiol 1999; 277:966-973.
17. Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001; 37:722-727. (Pubitemid 32199056)
18. Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16:638-645. (Pubitemid 41725100)
19. Li H, Ruan XZ, Powis SH, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int 2005; 67:867-874. (Pubitemid 41623311)
20. Schneider A, Zhang Y, Guan Y, et al. Differential, inducible gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre mice. Am J Physiol Renal Physiol 2003; 284:411-417.
21. Fujita A, Sasaki H, Doi A, et al. Ferulic acid prevents pathological and functional abnormalities of the kidney in Otsuka Long-Evans Tokushima Fatty diabetic rats. Diabetes Res Clin Pract 2008; 79:11-17.
22. Yang J, Zhang D, Li J, et al. Role of PPARgamma in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential. Clin Sci (Lond) 2009; 116:17-26.
23. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005; 68:285-292. (Pubitemid 43181387)
24. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54:2206-2211. (Pubitemid 40911285)
25. Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 2009; 60:170-173.
26. Flaquer M, Lloberas N, Franquesa M, et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci 2010; 87:147-153.
27. Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010; 33:144-149.
28. Pollex RL, Mamakeesick M, Zinman B, et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 2007; 21:166-171. (Pubitemid 46687068)
29. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53:1621-1629. (Pubitemid 38697679)
30. Schmidt MV, Brune B, von Knethen A. The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases. ScientificWorld-Journal 2010; 10:2181-2197.
31. Ryan KK, Li B, Grayson BE, et al. A role for central nervous system PPARgamma in the regulation of energy balance. Nat Med 2011; 17:623-626.
32. Duan SZ, Ivashchenko CY, Whitesall SE, et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 2007; 117:812-822. (Pubitemid 46348540)
33. Roszer T, Ricote M. PPARs in the renal regulation of systemic blood pressure. PPAR Res 2010; 2010:698730.
34. Kim HJ, Ham SA, Paek KS, et al. Transcriptional up-regulation of antioxidant genes by PPARdelta inhibits angiotensin II-induced premature senescence in vascular smooth muscle cells. Biochem Biophys Res Commun 2011; 406:564-569.
35. Todorov VT, Desch M, Schmitt-Nilson N, et al. Peroxisome proliferatoractivated receptor-gamma is involved in the control of renin gene expression. Hypertension 2007; 50:939-944. (Pubitemid 350287538)
36. Todorov VT, Desch M, Schubert T, Kurtz A. The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-gamma. Endocrinology 2008; 149:4647-4657.
37. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861-866. (Pubitemid 41161118)
38. Sugawara A, Uruno A, Kudo M, et al. Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease. Endocr J 2010; 57:847-852.
39. Desch M, Schreiber A, Schweda F, et al. Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells. Hypertension 2010; 55:660-666.
40. Wang N, Symons JD, Zhang H, et al. Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone. Toxicol Pathol 2009; 37:21-27.
41. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 2004; 83:93-102. (Pubitemid 39311284)
42. Horiki M, Ikegami H, Fujisawa T, et al. Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases. Diabetes Res Clin Pract 2004; 66 (Suppl 1):S63-S67. (Pubitemid 39572587)
43. Efrati S, Berman S, Ilgiyeav E, et al. PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron Exp Nephrol 2007; 106:e107-e112. (Pubitemid 47165837)
44. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007; 3:428-438. (Pubitemid 47123588)
45. Palmer AJ, Roze S, Rodby RA, et al. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Dtsch Med Wochenschr 2006; 131:1721-1726. (Pubitemid 44532020)
46. Sechi LA, De Carli S, Bartoli E. In situ characterization of renal insulin receptors in the rat. J Recept Res 1994; 14:347-356. (Pubitemid 24376634)
47. Tiwari S, Halagappa VK, Riazi S, et al. Reduced expression of insulin receptors in the kidneys of insulin-resistant rats. J Am Soc Nephrol 2007; 18:2661-2671. (Pubitemid 47531193)
48. Tiwari S, Sharma N, Gill PS, et al. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci USA 2008; 105:6469-6474. (Pubitemid 351758369)
49. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54:3095-3102. (Pubitemid 43334361)
50. Coward RJ, Saleem MA. Podocytes as a target of insulin. Curr Diabetes Rev 2011; 7:22-27.
51. Tojo A, Onozato ML, Kurihara H, et al. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003; 26:413-419. (Pubitemid 36701683)
52. Hosojima M, Sato H, Yamamoto K, et al. Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor-and insulinmediated signaling cross talk. Endocrinology 2009; 150:871-878.
53. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and dietinduced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293:1673-1677. (Pubitemid 32807849)
54. Jiang G, Dallas-Yang Q, Liu F, et al. Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)-and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. J Biol Chem 2003; 278:180-186. (Pubitemid 36043560)
55. Ohtomo S, Izuhara Y, Takizawa S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007; 72:1512-1519. (Pubitemid 350197953)
56. Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-952. (Pubitemid 351753281)
57. Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40:742-755.
58. Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci 2007; 96:346-356. (Pubitemid 46432031)
59. Liang YJ, Jian JH, Liu YC, et al. Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. Diabetes Metab Res Rev 2010; 26:406-416.
60. Gallicchio MA, Bach LA. Advanced glycation end products inhibit Na+ K+ ATPase in proximal tubule epithelial cells: role of cytosolic phospholipase A2alpha and phosphatidylinositol 4-phosphate 5-kinase gamma. Biochim Biophys Acta 2010; 1803:919-930.
61. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66:2137-2147. (Pubitemid 41115277)
62. Matsui T, Yamagishi S, Takeuchi M, et al. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interactionmediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2010; 398:326-330.
63. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007; 35:482-489. (Pubitemid 47261110)
64. Seliger SL. Inflammation and dyslipidemia in nephropathy: an epidemiologic perspective. Kidney Int 2006; 69:206-208. (Pubitemid 43323067)
65. Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89:47-58.
66. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52:2586-2593. (Pubitemid 37210549)
67. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292:1141-1150.
68. Tang SC, Leung JC, Chan LY, et al. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol 2006; 17:1633-1643. (Pubitemid 43794666)
69. Lee S, Kim W, Moon SO, et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006; 21:2096-2105. (Pubitemid 44295034)
70. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18:16-28. (Pubitemid 46053418)
71. Prabhakar S, Starnes J, Shi S, et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18:2945-2952. (Pubitemid 350058402)
72. Sommer M, Wolf G. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Am J Nephrol 2007; 27:425-434. (Pubitemid 47077207)
73. Sung B, Park S, Yu BP, Chung HY. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Exp Gerontol 2006; 41:590-599. (Pubitemid 43867228)
74. Arora MK, Reddy K, Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 2010; 636:137-144.
75. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56:1198-1209. (Pubitemid 46715598)
76. Wang C, Guan Y, Yang J. Cytokines in the progression of pancreatic betacell dysfunction. Int J Endocrinol 2010; 2010:515136.
77. Vionnet N, Tregouet D, Kazeem G, et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 2006; 55:3166-3174. (Pubitemid 44923657)
78. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645-1656. (Pubitemid 351632369)
79. Fujita H, Morii T, Koshimura J, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006; 53:745-752. (Pubitemid 46045119)
80. Ishizawa K, Dorjsuren N, Izawa-Ishizawa Y, et al. Inhibitory effects of adiponectin on platelet-derived growth factor-induced mesangial cell migration. J Endocrinol 2009; 202:309-316.
81. Guo Z, Zhao Z. Effect of N-acetylcysteine on plasma adiponectin and renal adiponectin receptors in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 558:208-213. (Pubitemid 46328886)
82. Nakamaki S, Satoh H, Kudoh A, et al. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood) 2011; 236:614-620.
83. Long Q, Lei T, Feng B, et al. Peroxisome proliferator-activated receptorgamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44. Endocrinology 2010; 151:3195-3203.
84. Zheng H, Li S, Ma L, et al. A novel agonist of PPAR-gamma based on barbituric acid alleviates the development of nonalcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Eur J Pharmacol 2011; 659:244-251.
85. Cha DR, Zhang X, Zhang Y, et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007; 56:2036-2045. (Pubitemid 47195832)
86. Cammisotto PG, Bendayan M. Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 2008; 39:579-584.
87. Hallows KR, Mount PF, Pastor-Soler NM, Power DA. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol 2010; 298:1067-1077.
88. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009; 76:145-148.
89. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54:3358-3370. (Pubitemid 43334324)
90. Awazu M, Omori S, Ishikura K, et al. The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003; 14:699-708. (Pubitemid 36246014)
91. Huang JS, Chuang LY, Guh JY, et al. Antioxidants attenuate high glucoseinduced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 293:1072-1082.
92. Kuan CJ, al-Douahji M, Shankland SJ. The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998; 9:986-993.
93. Wolf G, Schroeder R, Thaiss F, et al. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 1998; 53:869-879. (Pubitemid 28155659)
94. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006; 55:1666-1677. (Pubitemid 44324119)
95. Lai KN, Chan LY, Guo H, et al. Additive effect of PPAR-gamma agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011; 26:257-266.
96. Yuan Y, Zhang A, Huang S, et al. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Am J Physiol Renal Physiol 2011; 300:393-402.
97. Li X, Liu W, Wang Q, et al. Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol Cell Endocrinol 2009; 307:157-162.
98. Masson E, Lagarde M, Wiernsperger N, El Bawab S. Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: common or independent mechanisms? IUBMB Life 2006; 58:381-388. (Pubitemid 43995622)
99. Gong W, Liu ZH, Zeng CH, et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 2007; 72:213-218. (Pubitemid 47067392)
100. Peng A, Liu ZH, Zhou H, et al. Fibrillogenic amylin evokes the apoptosis of human mesangial cells. Diabetes Res Clin Pract 2007; 78:16-22. (Pubitemid 47348152)
101. Ikeda T, Iwata K, Ochi H. Effect of insulin, proinsulin, and amylin on renin release from perfused rat kidney. Metabolism 2001; 50:763-766. (Pubitemid 32700453)
102. Wookey PJ, Cao Z, Cooper ME. Interaction of the renal amylin and reninangiotensin systems in animal models of diabetes and hypertension. Miner Electrolyte Metab 1998; 24:389-399. (Pubitemid 29056249)
103. Hull RL, Shen ZP, Watts MR, et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005; 54:2235-2244. (Pubitemid 40911289)
104. Dai B, Liu Y, Mei C, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 2010; 119:323-333.
105. Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 2011; 108:2462-2467.
106. LeBrasseur NK, Kelly M, Tsao TS, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006; 291:175-181.
107. Liu Y, Dai B, Fu L, et al. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic Clin Pharmacol Toxicol 2010; 106:523-530.
108. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011; 300:465-474.
109. Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, et al. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Res 2010; 2010:274376.
110. Song J, Sakatsume M, Narita I, et al. Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clin Genet 2003; 64:398-403. (Pubitemid 37406888)
111. Xiao J, Leung JC, Chan LY, et al. Protective effect of peroxisome proliferatoractivated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol Dial Transplant 2009; 24:2067-2077.
112. Chan WL, Leung JC, Chan LY, et al. BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int 2008; 74:1026-1039.
113. Zachariah R, Reid SD, Chaillet P, et al. Viewpoint: why do we need a point-ofcare CD4 test for low-income countries? Trop Med Int Health 2011; 16:37-41.
114. Thabet MA, Chan JC. Vitamin E in renal therapeutic regiments. Pediatr Nephrol 2006; 21:1790-1801.
115. Gray B, Swick J, Ronnenberg AG. Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity. Nutr Rev 2011; 69:155-161.
116. Zuo Y, Yang HC, Potthoff SA, et al. Protective effects of PPAR{gamma} agonist in acute nephrotic syndrome. Nephrol Dial Transplant 2011. [Epub ahead of print]
117. Ozbek E, Ilbey YO, Simsek A, et al. Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats. Int Urol Nephrol 2010; 42:579-587.
118. Ozkaya O, Yavuz O, Can B, et al. Effect of rosiglitazone on cisplatin-induced nephrotoxicity. Ren Fail 2010; 32:368-371.
119. Arozal W, Watanabe K, Veeraveedu PT, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPARgamma agonist actions. Toxicology 2011; 279:91-99.
120. Collino M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 2005; 68:529-536. (Pubitemid 43323107)
121. Sivarajah A, Chatterjee PK, Patel NS, et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003; 23:267-276. (Pubitemid 36980722)
122. Doi S, Masaki T, Arakawa T, et al. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation 2007; 84:207-213. (Pubitemid 47205754)
123. Miglio G, Rosa AC, Rattazzi L, et al. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br J Pharmacol 2011; 162:111-125.
124. Yang HC, Deleuze S, Zuo Y, et al. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 2009; 20:2380-2388.
125. Zhang R, Zheng F. PPAR-gamma and aging: one link through klotho? Kidney Int 2008; 74:702-704.
126. Zhang H, Li Y, Fan Y, et al. Klotho is a target gene of PPAR-gamma. Kidney Int 2008; 74:732-739.
127. Yang H, Fogo AB. Cell senescence in the aging kidney. J Am Soc Nephrol 2010; 21:1436-1439.
128. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. (Pubitemid 46919772)